Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Bonache, Sandra|||0000-0002-7395-8143
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rueda, Oscar M.
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Polanska, Urszula|||0000-0003-1017-594X
  • Jones, Gemma|||0000-0002-7567-681X
  • Kristel, Petra
  • de Bustos, L.
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Montalban, Gemma|||0000-0002-6958-4759
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Fasani, Roberta|||0000-0003-1630-9988
  • Jiménez, Jose|||0000-0002-2576-1776
  • Howat, William J.
  • Dougherty, Brian|||0000-0002-0093-1142
  • Vivancos, Ana|||0000-0003-2888-6512
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Rubio Rodríguez, Isabel Teresa
  • Oaknin, Ana|||0000-0002-3592-7194
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Jonkers, Jos|||0000-0002-9264-9792
  • Diez, Orland|||0000-0001-7339-0570
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1 -loss in 20% and RAD51 -amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

  • Cedrés, Susana|||0000-0002-0648-7978
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Martinez de Castro, Ana
  • Pardo Aranda, Nuria
  • Navarro, Alejandro|||0000-0001-5903-270X
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Remon, Jordin
  • Zeron-Medina, Jorge
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Sansano, Irene|||0000-0003-0188-5210
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Mancuso, Francesco M.|||0000-0001-5499-6630
  • Serra, Violeta|||0000-0001-6620-1065
  • Vivancos, Ana|||0000-0003-2888-6512
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. We present a patient with a lung tumor with an exceptional response to cisplatin/gemcitabine in combination with HSP90i, which nowadays continues with HSP90i maintenance after three years. Whole-exome sequencing of the lung tumor unveiled a BRCA1/2 deficiency mutational signature, and mutation analysis confirmed a germline BRCA1 mutation. The striking efficacy of HSP90i plus chemotherapy vs chemotherapy alone was reproduced in a patient-derived xenograft (PDX) model from a breast cancer patient with a BRCA1 mutation (mean tumor volume [SD], No. of tumors: vehicle 8.38 [7.07] mm 3, n = 3; HSP90i 4.18 [1.93] mm 3, n = 5; cisplatin plus gemcitabine 3.31 [1.95] mm 3, n = 5; cisplatin plus gemcitabine plus HSP90i 0.065 [0.076] mm 3, n = 6). This case and the PDX demonstrate the efficacy for therapeutic inhibition of HSP90 in a BRCA- mutated patient, opening a new potential avenue for better identifying patients who might benefit most from HSP90i.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra, Violeta|||0000-0001-6620-1065
  • Wang, Anderson T.|||0000-0002-3571-5095
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Polanska, Urszula|||0000-0003-1017-594X
  • Palafox, Marta|||0000-0002-1762-3250
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Jones, Gemma|||0000-0002-7567-681X
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Armenia, Joshua|||0000-0002-9005-7769
  • Michopoulos, Filippos|||0000-0002-3667-6147
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Brough, Rachel|||0000-0002-1862-7130
  • Gulati, Aditi|||0000-0001-7476-2524
  • Pettitt, Stephen|||0000-0003-3313-3857
  • Bulusu, Krishna C.|||0000-0002-5092-6640
  • Nikkila, Jenni|||0000-0003-1380-8781
  • Wilson, Zena|||0000-0001-8811-4069
  • Hughes, Adina|||0000-0002-5711-627X
  • Wijnhoven, Paul W.G.|||0000-0002-5489-3006
  • Ahmed, Ambar|||0000-0002-5890-5035
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lau, Alan|||0000-0003-1055-9812
  • Critchlow, Susan|||0000-0002-4647-8988
  • Dougherty, Brian|||0000-0002-0093-1142
  • Caldas, Carlos|||0000-0003-3547-1489
  • Mills, Gordon|||0000-0002-0144-9614
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Forment, Josep V.|||0000-0002-7797-2583
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Lord, Christopher J.|||0000-0002-3226-0515
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • O'Connor, Mark J.|||0000-0003-1823-625X
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. We analyzed breast and ovarian patientderived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.